Drugs / Interleukin-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000769 | ? → Apr 1998 | HIV infectious disease, Kaposi's sarcoma | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00006113 Background | Jun 1999 → May 2003 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interleukin-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006113 ↗ |
| Known as | IL-4 | “To determine the safety and tolerance of interleukin-4 (IL-4) in patients with AIDS-related Kaposi's sarcoma.” NCT00000769 ↗ |
| Modality | Protein / enzyme biologic | “A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma” NCT00000769 ↗ |